Mutational rescue of the activity of high-fidelity Cas9 enzymes.
CP: Biotechnology
CP: Molecular biology
CRISPR
Cas9
HypaCas9
TurboCas9
gene editing
gene therapy
genome modification
off target
protein engineering
synthetic biology
Journal
Cell reports methods
ISSN: 2667-2375
Titre abrégé: Cell Rep Methods
Pays: United States
ID NLM: 9918227360606676
Informations de publication
Date de publication:
06 Apr 2024
06 Apr 2024
Historique:
received:
20
07
2023
revised:
02
01
2024
accepted:
20
03
2024
medline:
13
4
2024
pubmed:
13
4
2024
entrez:
12
4
2024
Statut:
aheadofprint
Résumé
Programmable DNA endonucleases derived from bacterial genetic defense systems, exemplified by CRISPR-Cas9, have made it significantly easier to perform genomic modifications in living cells. However, unprogrammed, off-target modifications can have serious consequences, as they often disrupt the function or regulation of non-targeted genes and compromise the safety of therapeutic gene editing applications. High-fidelity mutants of Cas9 have been established to enable more accurate gene editing, but these are typically less efficient. Here, we merge the strengths of high-fidelity Cas9 and hyperactive Cas9 variants to provide an enzyme, which we dub HyperDriveCas9, that yields the desirable properties of both parents. HyperDriveCas9 functions efficiently in mammalian cells and introduces insertion and deletion mutations into targeted genomic regions while maintaining a favorable off-target profile. HyperDriveCas9 is a precise and efficient tool for gene editing applications in science and medicine.
Identifiants
pubmed: 38608689
pii: S2667-2375(24)00087-0
doi: 10.1016/j.crmeth.2024.100756
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
100756Informations de copyright
Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests P.D.V., A.F., and O.R. are inventors of a patent application (Australian Provisional Patent Application 2020904609) filed by The University of Western Australia on designed Cas9 enzymes.